Figure 5.

miR-4461 knockdown ovarian cancer cells are sensitive to cisplatin treatment. (A) The expression of miR-4461 in cisplatin-resistant ovarian cancer cell lines was measured by real-time PCR. (B) Cell survival curves for HO8910 miR-4461 sponge or A2780 miR-4461 sponge and their control cells treated cisplatin with a dose escalation from 0 to 100 μg/ml. Data are presented as mean ± SD (n = 4) from one of three independent experiments. (C) Cell survival curves for HO8910 miR-4461 sponge or A2780 miR-4461 sponge and their control cells treated cisplatin (4 μg/ml) from 0 to 96 h. Data are presented as mean ± SD (n = 4) from one of three independent experiments. (D) HO8910 miR-4461 sponge or A2780 miR-4461 sponge and their control cells were treated with cisplatin (1 μg/ml) for 7 days and their colony growth was examined. (E) HO8910 miR-4461 sponge and its control cells were treated with cisplatin (4 μg/ml) for 48 h. The apoptotic cells were detected by flow cytometry. (7-AAD negative and Annexin V positive cells are the apoptotic cells). (F) A2780 miR-4461 sponge and its control cells were treated with cisplatin (4 μg/ml) for 48 h. The apoptotic cells were detected by flow cytometry. (7-AAD negative and Annexin V positive cells are the apoptotic cells). (G) HO8910 miR-4461 sponge or A2780 miR-4461 sponge and their control cells were treated with cisplatin (4 μg/ml) for 48 h. The cell extracts were subjected to western blotting with special antibody against PARP. *means p < 0.05, statistical difference.